Medincell
Medincell, a pioneering biopharmaceutical company headquartered in France, focuses on the development of innovative long-acting injectable therapies. Founded in 2000, the company has made significant strides in the industry, particularly in the fields of mental health and chronic diseases. Medincell's proprietary technology platform, which enables the sustained release of active pharmaceutical ingredients, sets it apart from competitors.
With a strong presence in Europe and expanding operations globally, Medincell is committed to addressing unmet medical needs through its core products, including its lead candidate for the treatment of schizophrenia. The company has garnered recognition for its unique approach to drug delivery, positioning itself as a leader in the biopharmaceutical sector. Medincell continues to advance its mission of improving patient outcomes through innovative therapeutic solutions.
+22 vs industry average
Medincell’s score of 60 is higher than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Medincell?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2028
Reported emissions
Scope 3 accounts for ••• of total emissions.
Medincell's reported carbon emissions
In 2025, Medincell reported total carbon emissions of approximately 3,000,000 kg CO2e, encompassing Scope 1, Scope 2, and Scope 3 emissions. The breakdown includes 980 kg CO2e from Scope 1, 11,270 kg CO2e from Scope 2, and a significant 2,988,750 kg CO2e from Scope 3 emissions. Notably, the Scope 3 emissions are primarily driven by purchased goods and services (1,884,020 kg CO2e) and business travel (506,120 kg CO2e). In 2024, Medincell's total emissions were approximately 3,000,000 kg CO2e, with Scope 1 emissions at 780 kg CO2e, Scope 2 at 40,820 kg CO2e, and Scope 3 emissions reaching 2,988,900 kg CO2e. The company has shown a commitment to transparency in its emissions reporting, disclosing data across all three scopes. Despite the detailed emissions reporting, Medincell has not set specific reduction targets or initiatives as part of its climate commitments. The absence of documented reduction initiatives or SBTi targets indicates a potential area for future development in their sustainability strategy. Overall, Medincell's emissions data reflects a comprehensive approach to understanding its carbon footprint, although further commitments to reduction strategies would enhance its climate action profile.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Medincell’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Medincell yet.
Scope 3 top emissions categories
7 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Climate initiatives

Science Based Targets Initiative

Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisationsUsage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project